Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, China.
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):710-4. doi: 10.1016/j.ijrobp.2009.08.065. Epub 2010 Feb 19.
To retrospectively compare the outcomes of patients with lymph node recurrence after radical surgery of esophageal cancer, when given radiotherapy with or without concurrent chemotherapy.
Between January 1996 and December 2005, the data from 73 patients with lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma were retrospectively reviewed. The patients were separated into two groups: radiochemotherapy (RC, 31 patients) and radiotherapy alone (RA, 42 patients). Patients in the RC group received at least two cycles of 5-fluorouracil/cisplatin chemotherapy concurrently with radiotherapy.
The median duration of follow-up was 11 months (range, 2-48). The overall survival rate for all patients was 46.7% and 4.7% at 1 and 3 years, respectively. The median overall survival time was 9 months (95% confidence interval, 6.96-11.04) and 17 months (95% confidence interval, 13.61-20.39) for RA and RC groups, respectively. The survival rate at 1 and 3 years was 62.5% and 10.5% in the RC group and 33.8% and 0% in the RA group (p = .0049, log-rank test; hazard ratio for death, 0.52; 95% confidence interval, 0.30-0.92). Acute toxicities were more frequent in the RC group than in the RA group. No significant differences were found in the late toxicity profiles between the two groups.
The results of the present retrospective analysis suggest that RC should be considered an effective and well-tolerated treatment of patients with thoracic esophageal squamous cell carcinoma and postoperative lymph node recurrence.
回顾性比较根治性手术后食管癌淋巴结复发患者接受放疗联合或不联合同期化疗的结果。
1996 年 1 月至 2005 年 12 月,回顾性分析 73 例胸段食管鳞癌根治术后淋巴结复发患者的资料。患者分为两组:放化疗组(RC 组,31 例)和单纯放疗组(RA 组,42 例)。RC 组患者至少接受两个周期的氟尿嘧啶/顺铂化疗联合放疗。
中位随访时间为 11 个月(范围,2-48)。所有患者的总生存率分别为 46.7%和 4.7%,1 年和 3 年。RA 组和 RC 组的中位总生存时间分别为 9 个月(95%置信区间,6.96-11.04)和 17 个月(95%置信区间,13.61-20.39)。RC 组 1 年和 3 年的生存率分别为 62.5%和 10.5%,RA 组分别为 33.8%和 0%(p =.0049,log-rank 检验;死亡风险比为 0.52;95%置信区间,0.30-0.92)。RC 组的急性毒性比 RA 组更常见。两组的晚期毒性谱无显著差异。
本回顾性分析结果表明,RC 应被视为治疗胸段食管鳞癌根治术后淋巴结复发患者的有效且耐受良好的治疗方法。